Review
Copyright ©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 533-557
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.533
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Impact of diabetes on various stages of chronic liver diseases. NAFLD: Non-alcoholic fatty liver disease; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; HCC: Hepatocellular carcinoma.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Mechanisms of action of hepatogenic diabetes.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Pros and cons of various glycemic markers. CLD: Chronic liver diseases; DM: Diabetes mellitus; IGT: Impaired glucose tolerance.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Pros and cons of various antihyperglycemic medications. NAFLD: Non-alcoholic fatty liver disease; HCC: Hepatocellular carcinoma; NASH: Nonalcoholic steatohepatitis.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Proposed diabetes treatment algorithm in patients with chronic liver diseases. CLD: Chronic liver diseases; DM: Diabetes mellitus; FPG: Fasting plasma glucose; OGTT: Oral glucose tolerance test; SGLT-2: Sodium-glucose cotransporter-2; GLP-1: Glucagon-like peptide-1; DPP-4: Dipeptidylpeptidase-4.